Train from scratch? Build upon open source? Leverage frontier models? In this episode, Dov Gertz (Cofounder and CEO) explains how Converge Bio is developing the most cutting-edge Generative AI models for Bioscience as the technology promises to transform the Life Sciences industry as we know it.

00:00 - Series AI Intro

00:40 -Pharma Industry and Converge Team Overview

05:00 - Empowering the Life Science Industry with Foundation Models

08:30 - The Landscape of Open and Proprietary Bioscience AI Models

13:37 - Why Scientific Rigor, and Transparency, is Essential

17:55 - Pharma's Rapid AI Adoption Curve

25:17 - How AI Fundamentally Alters the Business of Pharma

31:40 - Evolving Ahead of the Market

34:20 - Outro

Founders will talk about their gym regimens and yoga practices, but rarely do we hear about the mental health struggles many entrepreneurs encounter along their journey. In this episode we hear from Tzahi Weisfeld, GM of Intel Ignite, and Yariv Ganor, Startup Psychologist, as we explore the need to destigmatize Founder Mental Health issues and encourage all parties in the startup supply chain to engage in the discussion.

Mergers and Acquisitions are typically done by larger, more established companies. But in recent years, growth-stage startups have flexed their muscles in executing small acquisitions, whether to drive TAM expansion, accelerate product roadmaps, or strategically enter a new market/geography. In this episode, Ophir Reshef, CFO of Yotpo, describes how and why the Centaur ran an M&A strategy from its early days, and the many factors that other startups should consider when pursuing a similar route. Disclaimer: this episode was recorded just before the fundraising ecosystem hit the brakes.